新聞Roche acquired Ignyta for $1.7B on Jan 1st '18.Roche acquired the rights to the kinase inhibitor via its $1.7B acquisition of Ignyta in 2018.
新聞Foundation Medicine, Inc. partners with Ignyta.Foundation Medicine teamed up with Ignyta (a trial sponsor) and Pharmatech to present a poster at ASCO in 2017 demonstrating the utility of its trial education and access program for matching patients to studies targeting rare genomic findings.
新聞Roche acquired Ignyta for $1.7B on Dec 1st '17.Partin filled a crucial role in Roche's December 2017 tender offer to acquire biotech Ignyta Inc. for $1.7 billion.
